Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Leinco Technologies
CD194 (CCR4) (Mogamulizumab) Recombinant Human Monoclonal Antibody (KW-0761)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
LT1000-1MG
应用
建议稀释比
已发表文章
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG1, kappa
Expression System
HEK293 cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
KW-0761
抗原
Humanization of mouse anti-CCR4 mAb7.
偶联物
形式
Liquid
浓度
≥5.0 mg/mL
纯化类型
Protein A/G
保存液
PBS, pH 7.2-7.4
内含物
no preservative
保存条件
4°C short term, -80°C long term
运输条件
Ambient (domestic); Wet ice (international)
产品详细信息
Specificity: This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only.
Endotoxin Level: ≤ 1.0 EU/mg as determined by the LAL method. Purity: ≥95% monomer by analytical SEC.
Product Preparation: Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing: To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling: Functional grade biosimilar antibodies may be stored sterile as received at 2-8 C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80 C. Avoid Repeated Freeze Thaw Cycles.
This antibody has been tested in the following applications: Functional Assay, Flow Cytometry, ELISA, Depletion.
靶标信息
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sezary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions 8. On August 8 2018, the U. S. Food and pharmaceutical Administration (FDA) approved mogamulizumab injection (also known as Poteligeo) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sezary syndrome (SS) after at least one prior systemic therapy 7. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labor and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma 2.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
